Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.
• Male and female ages 50-85
• Patients who have three or more risk factors for Barrett's Esophagus.
• Gastroesophageal reflux disease defined by:
‣ Diagnosis
⁃ Use of one of the following drugs \>= 3 months over the last 5 years: omeprazole, esomeprazole, pantoprazole, rabeprazole, dexlansoprazole, lansoprazole, ranitidine, famotidine, cimetidine
⁃ prior endoscopic diagnosis of erosive esophagitis
• Body mass index (BMI) \>= 30
• Subjects with known or suspected BE (cases).
‣ Patient between the ages 18 - 90.
⁃ Patients with a BE segment ≥ 1cm in maximal extent endoscopically or suspected BE in medical record.
⁃ Histology showing evidence of intestinal metaplasia with or without presence of dysplasia or suspected BE in medical record.
⁃ Undergoing clinically indicated endoscopy.
• Subjects without known history of BE (controls).
‣ Undergoing clinically indicated diagnostic endoscopy.